Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
glioblastoma/tyrosine
Veza se sprema u međuspremnik
Stranica 1 iz 28 rezultatima
Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
INCLUSION CRITERIA:
1. Histologically confirmed World Health Organization (WHO) Grade IV glioblastoma.;
2. Radiographic evidence of tumour progression or recurrence;
3. The second-generation gene sequencing on pathological specimens and cerebrospinal fluid show at least one genetic mutation of the
FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
HMPL-813 in Treating Patients With Glioblastoma
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Epitinib could cross BBB and show its efficacy in brain metastasis tumors. Patients with histologically confirmed glioblastoma; standard treatment failed or no standard treatment as well as EGFR gene amplication are eligible. Patients will receive epitinib 120mg or 160mg epitinib daily. Epitinib is
Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
B. Lung Cancer Non-small cell lung cancer (NSCLC) is a common cause of cancer mortality throughout the world. In 2007, there were 1.5 million new lung cancer cases diagnosed worldwide, including around 733,100 cases in the South American Region.6
Approximately 85% of lung cancer is histologically
Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
High-grade gliomas of the central nervous system (CNS) are characterized by profound tumor related neo-angiogenesis, and intracranial perilesional edema. Glioblastoma (WHO-grade IV glioma) expresses high levels of VEGF and frequently carries an amplified gene copy numbers of the VEGFR2, KIT and
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Background:
- Zotiraciclib (TG02) is a pyrimidine-based multi-kinase inhibitor that has been shown to have inhibitory effects on CDKs, Janus Kinase 2 (JAK2) and Fm-like tyrosine kinase 3 (Flt3). It is orally administered and penetrates blood brain barrier (BBB). There is clinical experience in using
Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Gliomas account for almost 80% of primary malignant brain tumors, and glioblastoma is the most common subtype. Despite treatment with surgery, radiation, and chemotherapy(Temozolomide) almost all patients with glioma experience recurrence and the median survival for most patients is less than 2
Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Glioblastoma multiforme (GBM), the most common primary brain tumor in adults is known for its highly invasive and angiogenic profile. Despite advances in different modalities of GBM treatment, the overall prognosis of GBM remains dismal. The current standard of care is Radiation Therapy (RT) at a
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
The purpose of the study is to assess whether the use of genomics can identify patient specific treatment choices in glioblastoma (GBM) that improves clinical outcomes over standard of care. GBM is a devastating disease, the most common primary brain tumor and the most aggressive. With current
Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Glioblastoma (GBM), the most common and most malignant primary brain tumor, represents a major medical challenge considering its extremely poor prognosis (Wen 2008). Current standard of care includes maximal surgical resection, followed by concomitant radio-chemotherapy (temozolomide - TMZ) (RT-CT)
Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Increasing evidence suggests that clonal dominance of the drug target should be considered when stratifying therapeutics in solid tumours. It is likely that intratumour heterogeneity and cancer subclonal diversity may contribute to the high failure rate of oncology drugs relative to other medical
Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Despite intensive treatment efforts combining surgery, radio- and chemotherapy, the prognosis of patients suffering from glioblastoma (GBM) remains poor. Virtually all GBMs progress despite therapy. Patients receiving the standard therapy at primary disease have a median overall survival of 12-15
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Background
- Glioblastoma (GBM) is the most common primary brain tumor. With optimal treatment,consisting of focal radiotherapy with concurrent chemotherapy, followed by adjuvant chemotherapy, median survival is 14.6 months. Most patients have evidence of tumor progression within one year of
Najkompletnija baza ljekovitog bilja potpomognuta znanošću
- Radi na 55 jezika
- Biljni lijekovi potpomognuti znanošću
- Prepoznavanje bilja slikom
- Interaktivna GPS karta - označite bilje na mjestu (uskoro)
- Pročitajte znanstvene publikacije povezane s vašom pretragom
- Pretražite ljekovito bilje po učincima
- Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima
